Adeno-Associated Virus Serotype 5 (AAV5) differs from other parvovirus serotypes according to serological and DNA hybridization data, and AAV5 also uses different inverted terminal repeats (ITRs) compared to other AAV serotypes. AAV5 is the most efficient vector for transducing sensory neurons and is good at mediating gene transfer into human and murine airway epithelia. In addition, AAV5 vectors show a higher tropism for both mouse and human dendritic cells than AAV1, AAV2, AAV7, or AAV8.
These AAV particles constitutively express the firefly (Photinus pyralis) luciferase and mCherry genes connected via a T2A linker, under the control of a CMV promoter. The T2A self-cleaving peptide (derived from Thosea asigna virus 2A) leads to the efficient cleavage of the transcript, and expression of luciferase and mCherry as two separate proteins.
●
Product Data Gallery
Purified AAV5 Luciferase-mCherry particles.
Transduction of HEK293 cells using AAV5 Luciferase-mCherry particles.
Luciferase activity of HEK293 cells transduced by AAV5 Luciferase-mCherry particles.
Two vials (50 µl x 2) of AAV at a titer ≥1 x 1012 vector genomes/ml. The titer is determined by qPCR and will vary with each lot; the exact value will be provided with each shipment.
Purification
The purity of the AAV particles was confirmed to be greater than 90% by staining with One-Step Lumitein™ UV Protein Gel Stain (Biotium #21005-1L). Purity will vary with each lot; the exact value will be provided with each shipment.
Formulation
AAV5 was produced in HEK293-AAV cells and is supplied in PBS-MK (PBS Magnesium-Potassium) buffer containing 0.01% Pluronic F68.
Storage/Stability
AAV is shipped with dry ice. For long-term storage, it is recommended to store AAV at -80°C for up to 12 months from date of receipt. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle
Applications
Use as a positive control for transduction
Optimize transduction assays and track protein expression over time
Shipping Temperature
-80°C
Notes
Biosafety Recombinant AAV is inherently replication-deficient and not known to cause any human diseases. Additionally, following transduction, AAV vectors exist episomally and do not integrate into or disrupt the host cell’s genome. AAV requires the use of a Biosafety Level 1 facility. BPS Bioscience recommends following all local, federal, state, and institutional regulations and using all appropriate safety precautions.
Powered by Bioz
